CLRB Stock Overview A clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. More details
Rewards Risk Analysis + 2 more risks
See All Risk Checks Capture your thoughts, links and company narrative
Cellectar Biosciences, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Cellectar Biosciences Historical stock prices Current Share Price US$0.25 52 Week High US$4.45 52 Week Low US$0.22 Beta 0.87 1 Month Change -83.75% 3 Month Change -87.57% 1 Year Change -89.82% 3 Year Change -96.38% 5 Year Change -98.98% Change since IPO -100.00%
Recent News & Updates
Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring Dec 11
Cellectar Biosciences, Inc. announced delayed 10-Q filing Nov 14
Cellectar Biosciences, Inc. to Report Q3, 2024 Results on Nov 18, 2024 Nov 12
Cellectar Biosciences, Inc. to Present New Data from Phase 2 CLOVER -WaM Study in Oral Session at ASH 2024 Nov 08
Cellectar Biosciences Regains Compliance with Nasdaq Listing Rule 5250(c)(1) Regarding Filing of Form 10-Q Nov 02
Cellectar Biosciences Announces Receipt of Expected Delinquency Notification Letter from Nasdaq Aug 25 See more updates
Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring Dec 11
Cellectar Biosciences, Inc. announced delayed 10-Q filing Nov 14
Cellectar Biosciences, Inc. to Report Q3, 2024 Results on Nov 18, 2024 Nov 12
Cellectar Biosciences, Inc. to Present New Data from Phase 2 CLOVER -WaM Study in Oral Session at ASH 2024 Nov 08
Cellectar Biosciences Regains Compliance with Nasdaq Listing Rule 5250(c)(1) Regarding Filing of Form 10-Q Nov 02
Cellectar Biosciences Announces Receipt of Expected Delinquency Notification Letter from Nasdaq Aug 25 Cellectar Biosciences, Inc. announced delayed 10-Q filing Aug 15
No longer forecast to breakeven Aug 13
Cellectar Biosciences, Inc. to Report Q2, 2024 Results on Aug 13, 2024 Aug 09
We Think Cellectar Biosciences (NASDAQ:CLRB) Needs To Drive Business Growth Carefully Aug 08
Cellectar Biosciences, Inc. Announces Positive Results Data from its Ongoing CLover WaM Pivotal Study Evaluating Iopofosine I 131 for the Treatment of Relapsed/Refractory Waldenstrom's Macroglobulinemia Jul 23
Insufficient new directors Jul 01
Cellectar Biosciences, Inc. to Report Q1, 2024 Results on May 14, 2024 May 09
Cellectar Biosciences, Inc., Annual General Meeting, Jun 14, 2024 Apr 28
New minor risk - Market cap size Apr 19
New major risk - Financial position Mar 27
Price target increased by 23% to US$14.75 Mar 27
Cellectar Biosciences, Inc. to Report Fiscal Year 2023 Results on Mar 27, 2024 Mar 21
Cellectar Biosciences, Inc. Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer Mar 05
Cellectar Biosciences: A Shoestring Opportunity You're About To Miss Feb 12
New major risk - Shareholder dilution Feb 02
Cellectar Biosciences, Inc. Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1B Clinical Study Jan 31
Cellectar Biosciences, Inc. Reports Complete Central Nervous System (CNS) Clearance in Relapsed/Refractory Waldenstrom’s Macroglobulinemia Patient Jan 23
Forecast to breakeven in 2026 Jan 16
Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy for Solid Tumors and Releases Promising Preclinical Data Jan 16
Cellectar Biosciences Announces Positive Topline Data Achieving Primary Endpoint in Pivotal Clinical Study of Iopofosine I 131 in Waldenstrom's Macroglobulinemia Jan 08
Forecast to breakeven in 2026 Dec 31
New minor risk - Profitability Nov 17 Cellectar Biosciences, Inc. announced that it has received $102.9 million in funding from Aigh Capital Management, LLC, ADAR1 Capital Management, LLC, Second Line Capital, LLC, Nantahala Capital Management, LLC, AuGC Partners LLC, Rosalind Advisors, Inc.
Nasdaq Grants Cellectar Biosciences an Extension to Take Action to Evidence Compliance with Nasdaq Listing Rule 5550(b), on or Before January 4, 2024 Oct 28 Cellectar Biosciences, Inc. to Report Q3, 2023 Results on Nov 02, 2023 Oct 25
Cellectar Biosciences, Inc. Receives European Medicines Agency Priority Medicines (PRIME) Designation for Iopofosine for Waldenstrom's Macroglobulinemia Sep 19
Price target decreased by 7.7% to US$12.00 Sep 12 Cellectar Biosciences, Inc. announced that it expects to receive $102.9 million in funding from Aigh Capital Management, LLC, ADAR1 Capital Management, LLC, Second Line Capital, LLC, Nantahala Capital Management, LLC, AuGC Partners LLC, Rosalind Advisors, Inc. and other investors Sep 06
Cellectar Biosciences Receives Notice from Nasdaq Regarding Non-Compliance with Minimum Stockholders’ Equity Requirement Pursuant to Nasdaq Listing Rule 5550(b)(1) Aug 22
New major risk - Negative shareholders equity Aug 16
New minor risk - Share price stability Aug 07
Cellectar Biosciences, Inc. Provides an Update for Its iopofosine I 131 Clinical Program and Guidance Related to Its Proprietary Phospholipidether Drug Conjugate Platform Jun 13
Cellectar Biosciences Hires Dr. Andrei Shustov as New Senior Vice President, Medical Feb 16
Cellectar Biosciences, Inc. Announces Appointment of Shane Lea as Chief Commercial Officer Dec 01
Cellectar Biosciences, Inc. Announces Presentation of Data on CLR 12120 Series of Targeted Alpha-Emitting Therapies at the 13th Annual World ADC Conference Nov 22
Cellectar Biosciences, Inc. Announces Resolution of Breach of Contract and Intellectual Property Dispute Nov 17
Price target decreased to US$12.60 Nov 16
Price target decreased to US$33.63 Nov 03 Cellectar Biosciences, Inc. announced that it has received $3.911327 million in funding Oct 27
Cellectar Biosciences, Inc. Wins $2 Million Grant to Expand Its Ongoing Phase 1 Study of Iopofosine I 131 in Pediatric Brain Tumors Sep 23
Cellectar Biosciences, Inc. Announces Publication of Data from its Expansion Cohort of the Phase II CLOVER-1 Study Iopofosine I-131 in Relapsed/Refractory Multiple Myeloma in Nature’s Blood Cancer Journal Sep 14
Here's Why We're Watching Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn Situation Aug 23
Cellectar Biosciences GAAP EPS of -$1.22 misses by $0.19 Aug 05
Price target decreased to US$39.38 Jul 22
Cellectar announces reverse stock split Jul 21
Price target increased to US$5.88 May 26
We're Keeping An Eye On Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn Rate May 10
Nasdaq Grants Extension to Cellectar Biosciences Until October 31, 2022 to Regain Compliance May 08
Cellectar Biosciences, Inc., Annual General Meeting, Jun 15, 2022 May 02 Cellectar Biosciences Appoints Jarrod Longcor as Chief Operating Officer
Is Cellectar Biosciences (NASDAQ:CLRB) In A Good Position To Invest In Growth? Jan 20
Cellectar Biosciences, Inc. Presents Data from Its Ongoing Phase 2 Clover-1 Study of Iopofosine I-131 At the 63rd Ash Annual Meeting and Exposition Dec 14
Is Cellectar Biosciences (NASDAQ:CLRB) In A Good Position To Deliver On Growth Plans? Oct 05
Cellectar Biosciences, Inc. Announces the Completion of the Part A Portion of A Safety and Tolerability Study of Iopofosine I-131 (Iopofosine) in Combination with External Beam Radiation (Ebrt) in Relapsed or Refractory Head and Neck Cancer Sep 24
Price target decreased to US$5.38 Sep 16
High number of new directors Jul 31
Cellectar Presents Data in Waldenstrom’s Macroglobulinemia in Poster At the 2021 American Society of Clinical Oncology Annual Meeting Jun 05
Cellectar shares fall after mid-stage CLR 131 trial data fails to impress Jun 04
We're Hopeful That Cellectar Biosciences (NASDAQ:CLRB) Will Use Its Cash Wisely May 20
Cellectar Biosciences EPS beats by $0.03 May 10
Cellectar Biosciences, Inc. Receives Notification of Formal Grant of the Patent Titled Phospholipid-Ether Analogs as Cancer-Targeting Drug Vehicles by the Eurasian, Australian and Mexican Patent Authorities Apr 28
Cellectar gets notification of formal grant from Australian and Mexican patent authorities Apr 27
Cellectar Biosciences, Inc. Announces Japan Patent Office Granted Patent, Titled, 'Phospholipid-Ether Analogs as Cancer-Targeting Drug Vehicles' Mar 11
New 90-day low: US$1.74 Mar 05
Cellectar Biosciences, Inc. Initiates Pivotal Trial of CLR 131 in Waldenstrom’s Macroglobulinemia Jan 13
Cellectar commences pivotal trial of CLR 131 in a rare form bone marrow cancer Jan 12
Cellectar Biosciences, Inc. announced that it has received $20.5065 million in funding Dec 30
Cellectar Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $24.499984 million. Dec 25
Cellectar Biosciences, Inc. announced that it expects to receive $20.5 million in funding Dec 24
Cellectar Bio readies stock offering Dec 23
New 90-day high: US$2.66 Dec 22
New 90-day high: US$1.52 Dec 02
We're Keeping An Eye On Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn Rate Nov 30
Cellectar Biosciences EPS beats by $0.05 Nov 09
Cellectar Biosciences, Inc. Announces CLR 131 Has Demonstrated Preliminary Activity in Inoperable Brain Tumors in Phase 1 Study Nov 06
Cellectar Bio's lead asset shows encouraging action in early-stage study of pediatric tumors Nov 05
New 90-day low - US$1.13 Sep 03 Shareholder Returns CLRB US Biotechs US Market 7D 6.5% -3.3% -0.4% 1Y -89.8% -2.7% 24.8%
See full shareholder returns
Return vs Industry: CLRB underperformed the US Biotechs industry which returned -2.7% over the past year.
Return vs Market: CLRB underperformed the US Market which returned 24.8% over the past year.
Price Volatility Is CLRB's price volatile compared to industry and market? CLRB volatility CLRB Average Weekly Movement 23.3% Biotechs Industry Average Movement 10.7% Market Average Movement 6.3% 10% most volatile stocks in US Market 17.0% 10% least volatile stocks in US Market 3.1%
Stable Share Price: CLRB's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CLRB's weekly volatility has increased from 15% to 23% over the past year.
About the Company Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom’s macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin’s lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors.
Show more Cellectar Biosciences, Inc. Fundamentals Summary How do Cellectar Biosciences's earnings and revenue compare to its market cap? CLRB fundamental statistics Market cap US$10.46m Earnings (TTM ) -US$50.11m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) CLRB income statement (TTM ) Revenue US$0 Cost of Revenue US$0 Gross Profit US$0 Other Expenses US$50.11m Earnings -US$50.11m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/26 02:22 End of Day Share Price 2024/12/24 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Cellectar Biosciences, Inc. is covered by 11 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Kumaraguru Raja Brookline Capital Markets Keith Markey Griffin Securities Swayampakula Ramakanth H.C. Wainwright & Co.
Show 8 more analysts 
